| Name | Title | Contact Details |
|---|
Dungarvin is a national organization of privately owned companies that are dedicated to providing high quality, community-based supports to people with varying support needs. Founded in St. Paul, Minnesota in 1976, Dungarvin has grown to employ approximately 3,500 people who currently provide supports to over 3,200 individuals across 13 states. We believe all persons faced with the challenges of a disability have the same rights and the same basic needs as do other citizens without disabilities. Dungarvin`s mission and values apply to every person we serve, including those with significant behavioral, medical and physical challenges. We are committed to principles of self-determination, self-actualization, and to the preservation of dignity of each person we serve, regardless of the nature or degree of their needs. Dungarvin`s mission is respecting and responding to the choices of people in need of supports. Dungarvin provides a variety of individually tailored services and supports including supported living, day services, supported employment, case management, supported foster care, children`s services, respite care, elder care, host homes and supports for persons with traumatic brain injury and mental health needs in several states.
IMDS (Innovative Medical Device Solutions) provides comprehensive product development and supply chain management solutions for medical device companies, with a focus on the orthopedic industry. IMDS is the integration of the following companies: Leis
Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly`s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. We pride ourselves on creating a culture and work environment that is scientifically driven, ambitious, and collaborative. We encourage diversity of thought that leads to great innovation and are looking to add to our dynamic team great people who are driven to transform the lives of patients. We believe our Microbiome platform represents a best in class approach to developing biopharmaceutical agents from live biotherapeutic products. ABI-M201, our lead program in mildly to moderately active ulcerative colitis (UC), is currently in a phase 1b clinical trial. This program is part of a broader collaboration we established with Allergan in 2017 for gastrointestinal programs such as UC, Crohn`s disease and Irritable Bowel Syndromes with potential total development and commercial milestones of up to $2.8 billion. Our internal pipeline comprises first in class or best in class live microbial biotherapeutic approaches in areas such as oncology, immune mediated and metabolic disorders, and other areas of high medical need. Assembly is headquartered in Carmel, Indiana, while the R&D headquarters is in South San Francisco. The Company also has a microbiome manufacturing facility in Groton, CT, and offices in China.
Since 1859 the Central Connecticut Coast Y branches have served as community centers in the heart of the twenty-five towns we serve. Much of the Central Connecticut Coast Y’s work is supported by membership dues, program fees and grants, but central to...
KAI Research is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.